Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 이한길 | * |
| dc.date.accessioned | 2026-04-06T16:30:02Z | - |
| dc.date.available | 2026-04-06T16:30:02Z | - |
| dc.date.issued | 2026 | * |
| dc.identifier.issn | 0815-9319 | * |
| dc.identifier.other | OAK-39161 | * |
| dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/274999 | - |
| dc.description.abstract | Background and Aim: Potassium-competitive acid blockers (P-CABs) are a novel class of acid suppressants developed to overcome the limitations of proton pump inhibitors (PPIs), providing rapid and sustained acid suppression. While PPI-related adverse events (AEs) are well-documented, safety data on P-CABs remain limited. This study systematically reviewed AEs of P-CABs compared with PPIs, with a meta-analysis focusing on hypergastrinemia. Methods: Following a preregistered PROSPERO protocol (CRD42024565011), we searched for randomized controlled trials (RCTs) and observational studies comparing P-CABs and PPIs in patients with gastroesophageal reflux disease or peptic ulcer disease. Frequently reported AEs and serious AEs (SAEs) were qualitatively synthesized; hypergastrinemia was quantitatively analyzed using a random-effects model. Results: Ten RCTs and one observational study were included. Nine studies reported specific AEs, with diarrhea reported in seven studies and constipation, nasopharyngitis, and liver-related events, each reported in three. Most AEs had reporting rates below 5%, except diarrhea, nasopharyngitis, and upper respiratory tract inflammation, which exceeded 5% in both groups. Fracture demonstrated the largest relative difference between the groups, with a threefold higher rate in the P-CAB group. SAEs were observed in fewer than 10% of patients in both groups in most studies. A meta-analysis of six studies showed greater serum gastrin elevation in the P-CAB group compared with the PPI group (mean difference: 130.92 pg/mL, 95% confidence intervals: 36.37–225.47). Conclusions: P-CABs demonstrate a comparable AE risk to PPIs but monitoring for hypergastrinemia and hepatic dysfunction is essential. Further research is required to support safer clinical use. © 2025 The Author(s). Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. | * |
| dc.description.sponsorship | John Wiley and Sons Inc | * |
| dc.language | English | * |
| dc.subject | gastroesophageal reflux disease | * |
| dc.subject | meta-analysis | * |
| dc.subject | potassium-competitive acid blockers | * |
| dc.subject | proton pump inhibitors | * |
| dc.subject | systematic review | * |
| dc.title | Safety of Potassium-Competitive Acid Blockers Compared With Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease and Peptic Ulcer Disease: A Systematic Review and Meta-Analysis | * |
| dc.type | Review | * |
| dc.relation.issue | 1 | * |
| dc.relation.volume | 41 | * |
| dc.relation.index | SCIE | * |
| dc.relation.index | SCOPUS | * |
| dc.relation.startpage | 28 | * |
| dc.relation.lastpage | 40 | * |
| dc.relation.journaltitle | Journal of Gastroenterology and Hepatology (Australia) | * |
| dc.identifier.doi | 10.1111/jgh.70178 | * |
| dc.identifier.wosid | WOS:001629135600001 | * |
| dc.identifier.scopusid | 2-s2.0-105023881593 | * |
| dc.author.google | Jang Y. | * |
| dc.author.google | Park J. | * |
| dc.author.google | Kang D. | * |
| dc.author.google | Kim J. | * |
| dc.author.google | Choi H. | * |
| dc.author.google | Jeon H.-L. | * |
| dc.author.google | Lee H. | * |
| dc.contributor.scopusid | 이한길(56802870700) | * |
| dc.date.modifydate | 20260818161659 | * |